Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Blood
Inhye E AhnAdrian Wiestner

Abstract

The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and relapsed/refractory (RR) CLL. With the median follow-up of 4.8 years, 49 (57.0%) of 86 patients remain on study. Treatment was discontinued for progressive disease in 20 (23.3%) patients and for adverse events in 5 (5.8%). Atrial fibrillation occurred in 18 (20.9%) patients for a rate of 6.4 per 100 patient-years. No serious bleeding occurred. The overall response rate at 6 months, the primary study endpoint, was 95.8% for the TP53 cohort (95% confidence interval, 85.7%-99.5%) and 93.9% for the elderly cohort (95% confidence interval, 79.8%-99.3%). Depth of response improved with time: at best response, 14 (29.2%) of 48 patients in the TP53 cohort and 9 (27.3%) of 33 in the elderly cohort achieved a complete response. Median minimal residual disease (MRD) in peripheral blood was 3.8 × 10-2 at 4 years, with MRD-negative (<10-4) remissions in 5 (10.2%) patients. In the TP53 cohort, the estimated 5-year progression-free survival (PFS) was...Continue Reading

References

Mar 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip C AmreinJennifer R Brown
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
May 27, 2014·Haematologica·Paolo StratiWilliam G Wierda
May 30, 2014·The New England Journal of Medicine·Richard R FurmanY Lynn Wang
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Natalia L KomarovaDominik Wodarz
Oct 16, 2015·Nature·Dan A LandauCatherine J Wu
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Apr 19, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A WoyachJohn C Byrd
May 30, 2017·Cancer Cell·Michail S LionakisWyndham H Wilson
Jan 20, 2018·Nature Reviews. Cancer·Jan A Burger, Adrian Wiestner

❮ Previous
Next ❯

Citations

May 24, 2018·Expert Review of Hematology·Stefano Molica
Jul 13, 2018·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Aug 23, 2018·American Journal of Hematology·Anthony R MatoChadi Nabhan
Sep 18, 2018·Expert Opinion on Pharmacotherapy·Laura S Samples, Solomon A Graf
Nov 6, 2018·Drugs·Caspar da Cunha-Bang, Carsten Utoft Niemann
Oct 20, 2018·Current Hematologic Malignancy Reports·Bei HuNilanjan Ghosh
Dec 7, 2018·Hematology·Wei Ding
Dec 7, 2018·Hematology·Nitin Jain
May 6, 2019·Drugs & Aging·Paolo Strati, Alessandra Ferrajoli
May 18, 2019·American Society of Clinical Oncology Educational Book·Danielle BranderJacqueline C Barrientos
May 30, 2019·The New England Journal of Medicine·Adrian Wiestner
May 30, 2019·The New England Journal of Medicine·Nitin JainWilliam Wierda
Jun 14, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Kirollos S Hanna
Nov 26, 2019·The Cancer Journal·Prioty Islam, Anthony R Mato
Oct 9, 2019·Current Opinion in Oncology·Luana SchiattoneLydia Scarfò
Nov 28, 2019·Expert Review of Hematology·Riccardo MoiaGianluca Gaidano
Jan 31, 2020·Expert Opinion on Emerging Drugs·Stefano MolicaLuciano Levato
Jan 17, 2020·HemaSphere·Moritz FürstenauMichael Hallek
Apr 26, 2020·International Journal of Laboratory Hematology·Alba MoraCarol Moreno
Jul 30, 2020·The New England Journal of Medicine·Inhye E AhnAdrian Wiestner
Jul 30, 2020·The New England Journal of Medicine·Jan A Burger
Aug 5, 2020·Clinical Pharmacology and Therapeutics·Sathej GopalakrishnanKevin J Freise
May 15, 2020·Expert Opinion on Investigational Drugs·Elżbieta Iskierka-Jażdżewska, Tadeusz Robak
Jun 11, 2019·International Journal of Cancer. Journal International Du Cancer·Ambrus GángóCsaba Bödör
Nov 23, 2019·Expert Review of Hematology·Yasir KhanSusan O'Brien
Sep 27, 2019·Frontiers in Oncology·Ilaria Del GiudiceRobin Foà
May 26, 2018·Blood·Francesco Forconi
Apr 2, 2020·Nature Reviews. Cardiology·Joerg Herrmann
Jul 24, 2020·Expert Review of Hematology·Candida Vitale, Alessandra Ferrajoli
Mar 31, 2019·Targeted Oncology·Fabienne Lucas, Jennifer A Woyach
Dec 7, 2019·Hematology·Barbara EichhorstMichael Hallek
Jun 20, 2020·Expert Opinion on Drug Safety·Diana CrestanPaolo Baldo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.